Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
EBITDA before special items falls 1.3 percent to € 4.41 billion
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Acquisition of exclusive commercialization rights for European markets
An accomplished R&D leader and champion of the application of AI to drug discovery
Subscribe To Our Newsletter & Stay Updated
